Monica P Rodriguez1, Nick D Tsihlis1, Zachary M Emond1, Zheng Wang1, Vinit N Varu1, Qun Jiang1, Janet M Vercammen1, Melina R Kibbe2. 1. Division of Vascular Surgery, Department of Surgery, and Simpson Querrey Institute for BioNanotechnology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 2. Division of Vascular Surgery, Department of Surgery, and Simpson Querrey Institute for BioNanotechnology, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Division of Vascular Surgery, Department of Surgery, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois. Electronic address: mkibbe@nmh.org.
Abstract
BACKGROUND: Nitric oxide (NO) more effectively inhibits neointimal hyperplasia in type 2 diabetic versus nondiabetic and type 1 diabetic rodents. NO also decreases the ubiquitin-conjugating enzyme UbcH10, which is critical to cell-cycle regulation. This study seeks to determine whether UbcH10 levels in the vasculature of diabetic animal models account for the differential efficacy of NO at inhibiting neointimal hyperplasia. MATERIALS AND METHODS: Vascular smooth muscle cells (VSMCs) harvested from nondiabetic lean Zucker (LZ) and type 2 diabetic Zucker diabetic fatty (ZDF) rats were exposed to high glucose (25 mM) and high insulin (24 nM) conditions to mimic the diabetic environment in vitro. LZ, streptozotocin-injected LZ (STZ, type 1 diabetic), and ZDF rats underwent carotid artery balloon injury (±10 mg PROLI/NO), and vessels were harvested at 3 and 14 d. UbcH10 was assessed by Western blotting and immunofluorescent staining. RESULTS: NO more effectively reduced UbcH10 levels in LZ versus ZDF VSMCs; however, addition of insulin and glucose dramatically potentiated the inhibitory effect of NO on UbcH10 in ZDF VSMCs. Three days after balloon injury, Western blotting showed NO decreased free UbcH10 and increased polyubiquitinated UbcH10 levels by 35% in both STZ and ZDF animals. Fourteen days after injury, immunofluorescent staining showed increased UbcH10 levels throughout the arterial wall in all animal models. NO decreased UbcH10 levels in LZ and STZ rats but not in ZDF. CONCLUSIONS: These data suggest a disconnect between UbcH10 levels and neointimal hyperplasia formation in type 2 diabetic models and contribute valuable insight regarding differential efficacy of NO in these models. Published by Elsevier Inc.
BACKGROUND:Nitric oxide (NO) more effectively inhibits neointimal hyperplasia in type 2 diabetic versus nondiabetic and type 1 diabetic rodents. NO also decreases the ubiquitin-conjugating enzyme UbcH10, which is critical to cell-cycle regulation. This study seeks to determine whether UbcH10 levels in the vasculature of diabetic animal models account for the differential efficacy of NO at inhibiting neointimal hyperplasia. MATERIALS AND METHODS: Vascular smooth muscle cells (VSMCs) harvested from nondiabetic lean Zucker (LZ) and type 2 diabetic Zucker diabetic fatty (ZDF) rats were exposed to high glucose (25 mM) and high insulin (24 nM) conditions to mimic the diabetic environment in vitro. LZ, streptozotocin-injected LZ (STZ, type 1 diabetic), and ZDFrats underwent carotid artery balloon injury (±10 mg PROLI/NO), and vessels were harvested at 3 and 14 d. UbcH10 was assessed by Western blotting and immunofluorescent staining. RESULTS: NO more effectively reduced UbcH10 levels in LZ versus ZDF VSMCs; however, addition of insulin and glucose dramatically potentiated the inhibitory effect of NO on UbcH10 in ZDF VSMCs. Three days after balloon injury, Western blotting showed NO decreased free UbcH10 and increased polyubiquitinated UbcH10 levels by 35% in both STZ and ZDF animals. Fourteen days after injury, immunofluorescent staining showed increased UbcH10 levels throughout the arterial wall in all animal models. NO decreased UbcH10 levels in LZ and STZrats but not in ZDF. CONCLUSIONS: These data suggest a disconnect between UbcH10 levels and neointimal hyperplasia formation in type 2 diabetic models and contribute valuable insight regarding differential efficacy of NO in these models. Published by Elsevier Inc.
Authors: María D López-Avalos; Valérie F Duvivier-Kali; Gang Xu; Susan Bonner-Weir; Arun Sharma; Gordon C Weir Journal: Diabetes Date: 2006-05 Impact factor: 9.461
Authors: Nick D Tsihlis; Chris S Oustwani; Ashley K Vavra; Qun Jiang; Larry K Keefer; Melina R Kibbe Journal: Cell Biochem Biophys Date: 2011-06 Impact factor: 2.194
Authors: Vinit N Varu; Sadie S Ahanchi; Melissa E Hogg; Hussein A Bhikhapurwala; Amy Chen; Daniel A Popowich; Ashley K Vavra; Janet Martinez; Qun Jiang; Joseph E Saavedra; Joseph A Hrabie; Larry K Keefer; Melina R Kibbe Journal: Am J Physiol Heart Circ Physiol Date: 2010-06-18 Impact factor: 4.733
Authors: Sadaf S Ahanchi; Vinit N Varu; Nick D Tsihlis; Janet Martinez; Charles G Pearce; Muneera R Kapadia; Qun Jiang; Joseph E Saavedra; Larry K Keefer; Joseph A Hrabie; Melina R Kibbe Journal: Am J Physiol Heart Circ Physiol Date: 2008-10-17 Impact factor: 4.733
Authors: Charles G Pearce; Samer F Najjar; Muneera R Kapadia; Jozef Murar; Jason Eng; Brian Lyle; Oliver O Aalami; Qun Jiang; Joseph A Hrabie; Joseph E Saavedra; Larry K Keefer; Melina R Kibbe Journal: Free Radic Biol Med Date: 2007-09-25 Impact factor: 7.376
Authors: Nick D Tsihlis; Monica P Rodriguez; Qun Jiang; Amanda Schwartz; Megan E Flynn; Janet M Vercammen; Melina R Kibbe Journal: J Surg Res Date: 2016-01-30 Impact factor: 2.192